Communications between the CMO and theAntivirals and Therapeutics Taskforce

Louise Bicknell made this Freedom of Information request to Department of Health and Social Care

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

Department of Health and Social Care did not have the information requested.

Louise Bicknell
Delivered

Dear Department of Health and Social Care,

For the period 1 April 2022 to 6 September 2022

All direct communications between the Chief Medical Officer and the Antivirals and Therapeutics Taskforce (should this have its own email address or electronic identity) in which Evusheld (i.e. the combination of Tixagevimab and cilgavimab, AZD7742 or any other name that is used by the DHSC for this) is mentioned, whether by email or other electronic means.

Yours faithfully,

Louise Bicknell

Link to this Report
Department of Health and Social Care

1 Attachment

Dear Ms Bicknell,

Please find attached the Department of Health and Social Care's response
to your recent FOI request (our ref: FOI-1429201).

Yours sincerely, 

Freedom of Information Team
Department of Health and Social Care

show quoted sections

Link to this Report